Sirolimus

Leukemia

Masonic Cancer Center, University of MinnesotaSmall moleculePhase 2Active

B

62/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 60/ 100
Competitive Position: 65/ 100

Competitive context

123 Active assets in the Leukemia cohort.

Asset / Sponsor	Phase	Rating
Vincristine sulfate Inhye Ahn	Phase 3	BB
Cyclophosphamide National Cancer Institute (NCI)	Phase 4	BB
Daunomycin Richard Stone, MD	Phase 3	BB
Nivestim Hospital General de Mexico	Phase 4	BB
THIOGUANINE ANHYDROUS Incyte Corporation	Phase 3	BB

View all 50 →

Same molecule, other indications

Sirolimus is also rated in:

tuberous sclerosisActive

BBB

Indicative · Phase 3

73 / 100

disease related to transplantationDormant

BBB

Indicative · Phase 4

72 / 100

myelodysplastic/myeloproliferative neoplasmActive

BB

Indicative · Phase 2

69 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.